Off-label medication use in rare pediatric diseases in the United States-Reference-Cited by-同舟云学术

Off-label medication use in rare pediatric diseases in the United States

Published:2021-11-30 Issue:4 Volume:10 Page:238-245
ISSN:2186-361X
Container-title:Intractable & Rare Diseases Research
language:en
Short-container-title:IRDR

Author:

Fung Albert¹,Yue Xiaomeng²,Wigle Patricia R.¹,Guo Jeff J.¹

Affiliation:

1. Division of Pharmacy Practice & Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USA.

2. Joulé, Edison, New Jersey, USA.

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/irdr/10/4/10_2021.01104/_pdf

Reference34 articles.

1. 1. U.S. Congress. Pediatric research equity act of 2003. Public Law, 108155. https://www.congress.gov/108/plaws/publ155/PLAW-108publ155.pdf (accessed September 18, 2021).

2. 2. U.S. Congress. Best Pharmaceuticals For Children Act. Public Law, 107109. https://www.congress.gov/107/plaws/publ109/PLAW-107publ109.pdf (accessed September 18, 2021).

3. 3. Hoon D, Taylor MT, Kapadia P, Gerhard T, Strom BL, Horton DB. Trends in off-label drug use in ambulatory settings: 2006-2015. Pediatrics. 2019; 144:e20190896.

4. 4. Genetic and Rare Diseases (GARD) Information Center. FAQs about rare diseases. https://rarediseases.info.nih.gov/diseases/pages/31/fags-about-rare-diseases (accessed June 20, 2021).

5. 5. U.S. Congress. Orphan Drug Act. Public Law, 97144. https://www.fda.gov/media/99546/download (accessed September 18, 2021).

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterizing Families of Pediatric Patients with Rare Diseases and Their Diagnostic Odysseys: A Comprehensive Survey Analysis from a Single Tertiary Center in Korea;Annals of Child Neurology;2024-07-01

2. Magnetic Nanoparticle‐Assisted Non‐Viral CRISPR‐Cas9 for Enhanced Genome Editing to Treat Rett Syndrome;Advanced Science;2024-04-22

3. Paving the Path for Sustainable and Responsible Off-Label Use of Pharmaceutical Products in Europe;European Journal of Health Law;2024-03-13

4. Navigating the unknown: how to best ‘reflect’ standard of care in indications without a dedicated treatment pathway in health technology assessment submissions;Journal of Comparative Effectiveness Research;2024-02

5. Should secondary pharmacogenomic variants be actively screened and reported when diagnostic genome-wide sequencing is performed in a child?;Genetics in Medicine;2024-02